Results 241 to 250 of about 69,641 (328)

Tumor desialylation surpasses anti‐PD‐L1 checkpoint therapy in restoring anti‐tumor immunity in a murine model for colorectal cancer

open access: yesInternational Journal of Cancer, Volume 157, Issue 9, Page 1948-1962, 1 November 2025.
What's new? Our research highlights how tumor sialylation affects tumor growth and reshapes the immune tumor microenvironment in colorectal cancer. We demonstrate for the first time that complete removal of sialic acids from colorectal tumor cells elicits a robust anti‐tumor immune response, but does not enhance anti‐PD‐L1 blockade efficacy.
Irene van der Haar Àvila   +11 more
wiley   +1 more source

Trial Readiness: Understanding the Natural History of Rare Diseases

open access: yesJournal of Inherited Metabolic Disease, Volume 48, Issue 6, November 2025.
ABSTRACT Inherited metabolic diseases (IMD) represent the largest and still growing group of treatable genetic disorders and are increasingly amenable to targeted interventions that achieve varying degrees of prognostic improvement. Innovative therapies are on the horizon and offer promising opportunities for disease‐changing treatment for a variety of
Thomas Opladen   +6 more
wiley   +1 more source

Quantitative analysis of inhibitor‐induced assembly disruption in human UDP‐GlcNAc 2‐epimerase using mass photometry

open access: yesProtein Science, Volume 34, Issue 11, November 2025.
Abstract Uridine diphosphate N‐acetylglucosamine (UDP‐GlcNAc) 2‐epimerase (GNE)/N‐acetylmannosamine kinase is the rate‐limiting enzyme in sialic acid biosynthesis and a promising therapeutic target. We applied mass photometry (MP) to investigate GNE oligomerization and its modulation by three small‐molecule inhibitors (C5, C13, and C15).
Nico Boback   +4 more
wiley   +1 more source

Role of sialic acid in erythrocyte survival [PDF]

open access: bronze, 1975
JR Durocher, RC Payne, Conrad Me
openalex   +1 more source

Home - About - Disclaimer - Privacy